Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosis

Clinical Biochemistry

Volumn 46, Issue 7-8, 2013, Pages 698-700

  Smith, Miriam J ^a,d   Esparza, Sonia ^a   Merker, Vanessa L ^a   Muzikansky, Alona ^a   Bredella, Miriam A ^a   Harris, Gordon J ^a   Kassarjian, Ara ^b   Cai, Wenli ^a   Walker, James A ^a   Mautner, Victor F ^c   Plotkin, Scott R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Biostatistics Center ^*  (Spain)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Biomarker; Neurofibroma; Neurofibromatosis; S100 ; Schwannoma

Indexed keywords

PROTEIN S100B; NERVE GROWTH FACTOR; PROTEIN S 100; S 100 CALCIUM BINDING PROTEIN BETA SUBUNIT; S-100 CALCIUM-BINDING PROTEIN BETA SUBUNIT;

ACOUSTIC NEURINOMA; ADULT; ARTICLE; ASTROCYTE; CHI SQUARE TEST; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NEURILEMOMA; NEUROFIBROMATOSIS; OLIGODENDROGLIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SCHWANN CELL; TUMOR VOLUME; WHOLE BODY MRI; BLOOD; NEUROMA; PATHOLOGY;

ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; NEUROFIBROMATOSES; NEUROFIBROMATOSIS 1; NEUROFIBROMATOSIS 2; NEUROMA, ACOUSTIC; S100 PROTEINS; TUMOR BURDEN;

EID: 84884809450     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.12.007     Document Type: Article

References (11)

1. Vogelbaum M.A., Masaryk T., Mazzone P., Mekhail T., Fazio V., McCartney S., et al. S100beta as a predictor of brain metastases: brain versus cerebrovascular damage. Cancer 2005, 104:817-824.
2. Blyth B.J., Farhavar A., Gee C., Hawthorn B., He H., Nayak A., et al. Validation of serum markers for blood-brain barrier disruption in traumatic brain injury. J Neurotrauma 2009, 26:1497-1507.
3. Kruijff S., Bastiaannet E., Kobold A.C., van Ginkel R.J., Suurmeijer A.J., Hoekstra H.J. S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol 2009, 16:3455-3462.
4. Kanner A.A., Marchi N., Fazio V., Mayberg M.R., Koltz M.T., Siomin V., et al. Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions. Cancer 2003, 97:2806-2813.
5. Plotkin S.R., Bredella M.A., Cai W., Kassarjian A., Harris G.J., Esparza S., et al. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One 2012, 7:e35711.
6. Portela L.V., Tort A.B., Schaf D.V., Ribeiro L., Nora D.B., Walz R., et al. The serum S100B concentration is age dependent. Clin Chem 2002, 48:950-952.
7. Friedman J.M. Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol 2002, 17:548-554.
8. Baser M.E., Kuramoto L., Woods R., Joe H., Friedman J.M., Wallace A.J., et al. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. J Med Genet 2005, 42:540-546.
9. Hummel T.R., Jessen W.J., Miller S.J., Kluwe L., Mautner V.F., Wallace M.R., et al. Gene expression analysis identifies potential biomarkers of neurofibromatosis type 1 including adrenomedullin. Clin Cancer Res 2010, 16:5048-5057.
10. Miller S.J., Jessen W.J., Mehta T., Hardiman A., Sites E., Kaiser S., et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. EMBO Mol Med 2009, 1:236-248.
11. Kolanczyk M., Mautner V., Kossler N., Nguyen R., Kuhnisch J., Zemojtel T., et al. MIA is a potential biomarker for tumour load in neurofibromatosis type 1. BMC Med 2011, 9:82.